Uwell Biopharma, Inc. (TPEX:7902)

Market Cap	9.20B
Revenue (ttm)	450.00K
Net Income	-54.86M
EPS	-0.47
Shares Out	200.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,843,206
Average Volume	1,406,019
Open	49.95
Previous Close	49.95
Day's Range	44.90 - 49.95
52-Week Range	7.80 - 51.50
Beta	n/a
RSI	70.50
Earnings Date	n/a

About Uwell Biopharma

Uwell Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel cancer immunotherapeutic in Taiwan. The company provides chimeric antigen receptor T-cell (CAR-T) therapy platforms, lentiviral vector production, and related services. The company was founded in 2020 and is based in New Taipei City, Taiwan.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2020
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7902